Annovis Bio - ANVS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.75
  • Forecasted Upside: 138.61%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.63
▼ -0.57 (-4.67%)

This chart shows the closing price for ANVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Annovis Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANVS

Analyst Price Target is $27.75
▲ +138.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $27.75, with a high forecast of $36.00 and a low forecast of $9.00. The average price target represents a 138.61% upside from the last price of $11.63.

This chart shows the closing price for ANVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Annovis Bio. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00Low
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00Low
2/28/2024Brookline Capital ManagementDowngradeBuy ➝ Hold$9.00Low
12/29/2023Canaccord Genuity GroupInitiated CoverageBuy$36.00Low
12/29/2023Canaccord Genuity GroupInitiated CoverageBuy$36.00Low
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00Low
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $30.00Low
11/10/2023Brookline Capital ManagementReiterated RatingBuy$35.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$40.00Low
4/21/2023HC WainwrightReiterated RatingBuy$40.00Low
2/8/2023HC WainwrightReiterated RatingBuy$40.00Low
9/8/2022HC WainwrightInitiated CoverageBuy$40.00Low
5/2/2022LADENBURG THALM/SH SHInitiated CoverageBuyHigh
10/8/2021Maxim GroupInitiated CoverageBuy$70.00Low
7/7/2021Maxim GroupBoost TargetBuy$45.00 ➝ $150.00High
5/21/2021Maxim GroupInitiated CoverageBuy$45.00High
5/13/2021Maxim GroupBoost TargetBuy$12.00 ➝ $45.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/17/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Annovis Bio logo
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Read More

Today's Range

Now: $11.63
Low: $11.59
High: $12.20

50 Day Range

MA: $10.37
Low: $8.47
High: $12.20

52 Week Range

Now: $11.63
Low: $5.42
High: $22.49

Volume

132,877 shs

Average Volume

283,305 shs

Market Capitalization

$128.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Annovis Bio?

The following Wall Street analysts have issued research reports on Annovis Bio in the last year: Brookline Capital Management, Canaccord Genuity Group Inc., and HC Wainwright.
View the latest analyst ratings for ANVS.

What is the current price target for Annovis Bio?

4 Wall Street analysts have set twelve-month price targets for Annovis Bio in the last year. Their average twelve-month price target is $27.75, suggesting a possible upside of 138.6%. Canaccord Genuity Group Inc. has the highest price target set, predicting ANVS will reach $36.00 in the next twelve months. Brookline Capital Management has the lowest price target set, forecasting a price of $9.00 for Annovis Bio in the next year.
View the latest price targets for ANVS.

What is the current consensus analyst rating for Annovis Bio?

Annovis Bio currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANVS.

What other companies compete with Annovis Bio?

How do I contact Annovis Bio's investor relations team?

Annovis Bio's physical mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company's listed phone number is 610-727-3913 and its investor relations email address is [email protected]. The official website for Annovis Bio is www.annovisbio.com. Learn More about contacing Annovis Bio investor relations.